What Is Barinthus Biotherapeutics plc (BRNS) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Barinthus Biotherapeutics plc. Trading at $0.65 against an estimated intrinsic value of $1.40, 8 of 9 active models flag meaningful upside of +114.1% on average. The most optimistic model, Regime Cross, places fair value at $2.15 (+229.1%), while First Chicago — the most conservative — estimates $0.60 (-8.8%). This +237.9% gap reflects genuine analytical uncertainty about Barinthus Biotherapeutics plc's intrinsic worth.
What Do the Models Say About BRNS?
9 of 13 models are currently active for BRNS. Of these, 8 models suggest upside while 1 model suggests overvaluation. The Bayesian DCF estimates BRNS's intrinsic value at $0.93, implying +42.4% upside from the current price. See which stocks rank higher →
How Does BRNS Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, BRNS ranks #123 by Quality of Company score. CirclFi's QOC score of 6.0/10 evaluates 32 fundamental signals. A score of 6.0 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Barinthus Biotherapeutics plc competes in an environment where pipeline depth and stage distribution often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is BRNS a Value Trap?
CirclFi's Value Trap algorithm assigns BRNS a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Barinthus Biotherapeutics plc. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Barinthus Biotherapeutics plc is rated at 6.0/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.
The gap between the most bullish and bearish model spans +237.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every BRNS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across BRNS's 9 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad